Under Dr. Anil Bhansali's clinical leadership, Gini has built one of the most rigorous semaglutide outcomes programmes in North India. Unlike commercial prescribers who dispense Ozempic on demand, Gini's approach is data-driven — every patient is assessed before prescription, monitored through therapy, and their outcomes tracked in Dr. Bhansali's cohort.
📍 Sector 69, Mohali · GLP-1 Desk: 0172 4120100 · Mon–Sat 10 AM–6 PM
Both are semaglutide — the exact same molecule, the exact same mechanism. The difference is the approved indication, dose range, and pen configuration.
At Gini, Dr. Bhansali selects the appropriate formulation and dose range based on your diagnosis and treatment goals — not based on which brand name you request. The clinical decision involves: your primary diagnosis (diabetes vs obesity), your HbA1c and weight targets, cardiovascular risk profile, and cost considerations.
Also available: Rybelsus (oral semaglutide tablets) — ₹3,500–5,500/month for injection-averse patients.
Not every patient needs Mounjaro. Semaglutide is the right first-line GLP-1 for many clinical profiles — and the clearly superior choice for specific ones.
For Type 2 diabetes with moderate glycaemic elevation and BMI under 35, semaglutide provides excellent HbA1c reduction with a strong safety and evidence record. A well-established first-line GLP-1 choice.
Patients seeking clinically meaningful but not maximal weight loss achieve 8–12% with semaglutide in Gini's cohort. For this target range, the additional cost of tirzepatide may not be justified.
Semaglutide is approximately 30–40% cheaper than tirzepatide at equivalent doses. For patients on a budget, Ozempic or Rybelsus (oral, ₹3,500–5,500/month) provide significant clinical benefit at lower cost.
Semaglutide has the strongest long-term cardiovascular evidence of any GLP-1 agonist: SUSTAIN-6 (T2D + CV disease) and SELECT trial (20% reduction in MACE in non-diabetic obese patients). For patients with prior MI, stroke, or heart failure, semaglutide is the preferred GLP-1.
Patients who have previously tolerated a GLP-1 agonist well are good candidates for semaglutide maintenance, particularly if their current control is satisfactory and they are not GLP-1 non-responders.
Non-diabetic patients with BMI above 30 and weight-related conditions (hypertension, sleep apnea, dyslipidaemia) who need the maximal 2.4mg dose are prescribed Wegovy — the appropriate formulation for this indication.
Gini Cohort Data (Semaglutide Group)
In the above patient profile groups, our data shows: average weight loss 8–12% of body weight at 6 months. HbA1c reduction of 1.4–2.0 percentage points. These are outcomes tracked in Dr. Bhansali's programme — not manufacturer trial data.
Semaglutide pricing in India after the November 2025 Novo Nordisk price reduction. Generic semaglutide expected — see notes below.
November 2025 Price Cut
Novo Nordisk implemented a 37% price reduction on Wegovy in November 2025 to improve access. This was in anticipation of the March 2026 patent expiry.
Generic Semaglutide — March 2026 Patent Expiry
Following patent expiry, domestic generic manufacturers are in the pipeline. As of April 2026, no generic semaglutide has received CDSCO approval. Call 0172-4120100 for current guidance.
Gini does not prescribe semaglutide without a structured baseline assessment. This is what separates a clinical programme from a commercial weight loss clinic.
GI side effects are the most common and are concentrated in the first few weeks of therapy. Slow dose titration significantly reduces severity.
For full CGHS + GLP-1 coverage details, see GLP-1 & CGHS Coverage →
For a full comparison of GLP-1 drugs and drug directory, see GLP-1 Therapy Mohali — Full Drug Directory and Comparison →
The strongest cardiovascular evidence of any GLP-1. Data-driven prescribing, not demand-driven. Assessment before prescription. Outcomes tracked. Mon–Sat, 10 AM–6 PM.